Treatment Method

ABSTRACT

A treatment composition for treating or preventing bovine mastitis, the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.

TECHNICAL FIELD

This invention relates to a treatment method.

In particular it relates to a method of treating bovine mastitis, and amethod of producing the treatment composition.

BACKGROUND ART

Mastitis is an inflammatory disease of the mammary gland of a mammal.

The inflammation is the result of infection by any of a multitude ofbacteria, mycoplasmas, yeast and fungi. The range of different organismsthat can cause mastitis and their varying susceptibilities toantibiotics presents the greatest challenge in the treatment andprevention of mastitis in dairy cows.

Bovine mastitis may be caused by Gram negative bacteria such asEscherichia coli, Klebsiella species and Enterbacter species, or byGram-positive bacteria such as Staphylococcus aureus, Enterococcispecies, and Streptococci such as Streptococcus uberus, Streptococcusagalactiae and Streptococcus dysgalactiae, and by Mycoplasma bovis.

Bacterial infection via the teats is the most common cause of mastitis.There is an increased risk of intra-mammary infection during the dryperiod because the teat is no longer protected by the flow of milkthrough the teat. Milk is known to have a natural anti-microbial action.Dairy cows are bred for increased milk production. There is a negativecorrelation between milk production capacity and resistance to mastitis,attributable in part to the increased metabolic stress associated withthe synthesis of milk. The large volume of milk may also overwhelm thenatural defense systems in the udder.

The teat canal plays a large part in preventing infections in the teatand udder such as mastitis. The teat canal has several anatomical andphysiological features that serve as a barrier to penetration bybacterial.

The normal teat canal represents a physical barrier to the penetrationof bacteria and is the single most important barrier to udder infection.Essentially, there are three main defense mechanisms offered by the teatcanal: adsorptive capacity of keratin for bacteria, desiccation of thecanal lumen and desquamation of the keratin lining during milk flow.

Besides being a physical barrier, the canal also contains long chainfatty acids produced by continuous keratinization of epithelial cellsthat are antibacterial, and a protein called ubiquitin that acts as ageneral antiseptic against incoming bacteria. In a healthy teat, thekeratin plug mechanically traps debris and bacteria and absorb themwithin the extracellular lipid film (Bramley and Dodd, 1984).

Epithelial desquamation and milk flow during lactation limit bacterialcolonization in the teat canal. However, at the beginning of the dryperiod when milk production ceases, bacteria are able to colonize theteat canal, and multiply and subsequently infect the mammary gland.

Teat seal formulations are currently available—however it is not knownfor these to include milk components, such as lactoferrin orlactoperoxidase. These form a physical barrier to the teat canal,thereby preventing entry of micro-organisms during the dry period. Someof these formulations include antibiotics, or chemicals known to haveanti-microbial activity. Antibiotics require withholding periods whichcan increase the time and effort required by the farmer, and may noteffectively target the pathogens causing the mastitis.

The primary treatment for bovine mastitis is the administration ofantibiotics such as penicillin. Antibiotics belonging to the penicillinand cephalosporin family are most effective against Gram-positivebacteria and have poor or strain-dependent activity againstGram-negative pathogens. A study in Poland (Malinowski et al, 2002)found that out of 517 strains of Staphylococcus aureus from subclinicaland clinical mastitis, more than 60% were resistant to penicillin andampicillin, more than 40% were resistant to amoxicillin, 30% wereresistant to cephalosporin, 26% were resistant to tetracycline orerythromycin and 54-55% were resistant to lincomycin. Aminoglycosideshave a broader spectrum of activity but are not effective againstbacteria with rapid growth.

Bovine mastitis is of considerable economic significance to the dairyindustry. This is particularly due to the following:

-   -   the high cost of the treatment,    -   the loss of milk during the infected period, and subsequent        withholding period following the use of antibiotics. if        antibiotics are found in the milk supplied to a dairy company,        the whole batch may need to be discarded, and the farmer may        face large penalties.    -   cross-contamination within the herd    -   long-term loss of milk over the life of the animal due to        decreased mammary capacity

A number of milk components have previously been isolated, purified anddiscussed in relation to use to prevent or treat mastitis, theseinclude:

Lactoferrin (Lf), a glycoprotein which is present in mammary glandsecretion and many other exocrine secretions of mammals, Lf is secretedpredominately by surface epithelia into the mucosal environment.Lactoferrin is a multifunctional protein that has antibacterial,antifungal, antiviral, antitumour, anti-inflammatory, andimmunoregulatory properties

Lf is produced at high levels in nasal and tracheal passages, and ingastric, genital and opthalmic secretions. Lf is also produced at highlevels in neutrophils where it is stored in secondary granules andreleased during inflammation.

The mechanism by which Lf inhibits microbial growth has not been fullyelucidated. Its antimicrobial and anti-inflammatory effects are believedto be as a result of a number of different actions or functions of Lf.

The highly basic N terminal region of bovine lactoferrin is essentialfor antimicrobial activity. The 25 N-terminal amino acids may be removedby proteases to form Lactoferricin (Lfcin). These proteases may benaturally occurring in milk or serum, and many micro-organisms produceproteases. LFcin is up to a 1000 fold more effective against somemicro-organisms than intact lactoferrin. Lfcin has been shown to inhibita diverse range of microorganisms such as gram-negative bacteria,gram-positive bacteria, yeast, filamentous fungi, and parasiticprotozoa, including some antibiotic-resistant pathogens.

Lf binds to lipopolysaccharide. When Gram-negative bacteria are killedby the natural defense system of the animal or by antimicrobial agentsthe release of lipopolysaccharide from the cell walls of the bacteriaprovokes an inflammatory response. One of the primary actions of Lftherefore is to bind the LPS and prevent the inflammatory response. Lfalso displays an immunomodulatory role by binding with high affinity tobacterial endotoxin, thus protecting against endotoxin lethal shock.

Lf is also an iron binding glycoprotein. Most micro organisms need ironfor growth and therefore Lf has the potential to inhibit the growth ofbacteria and even kill them by depriving them of iron. The effectivenessof the anti-bacterial activity of Lf depends on the iron requirement ofthe organism, being availability of exogenous iron, and theconcentration and degree of iron saturation of Lf. It has been shownthat natural Lf is bacteriostatic against a wide range of microorganisms, including gram negative bacteria with high iron requirements,and some gram positive organisms such as Staphylococcus aureus which isa major mastitis pathogen.

Current commercial applications of bovine Lf include infant formulas,fermented milks, nutritional iron supplements, chewing gums,immune-enhancing nutraceuticals, cosmetic formulas and feed and pet caresupplements.

The increased concentrations of endogenous Lf in milk during the dryperiod, and the bacteriostatic and bactericidal effects of exogenous Lfhave lead to research in the use of Lf for treating or preventingmastitis. This research has in the past focused on increasing the purityand extraction rates of Lf to increase the beneficial effect.

Another milk component is Lactoperoxidase (Lp), a protein present in themammary gland secretion and many other exocrine secretions of mammals.

The Lactoperoxidase system consists of three components—lactoperoxidase,thiocyanate and hydrogen peroxide, which are all present in fresh milk.Lp catalyses the oxidation of thiocyanate by peroxide and generatesintermediate products with antibacterial properties. Mammalian cells arenot affected by these oxidation products and the Lp system may actuallyprotect cells against the toxic effects of hydrogen peroxide.Thiocyanate is present in the mammary, salivary and thyroid glands andtheir secretions, in synovial, cerebral, cervical and spinal fluids, inlymph and plasma, and in organs such as stomach and kidney. Hydrogenperoxide, the third component of the Lactoperoxidase system is notnormally detected in milk. It may be generated endogenously bypolymorphonuclear leucocytes in the process of phagocytosis.Lactobacilli, lactococci and streptococci produce sufficient hydrogenperoxide under aerobic conditions to activate the Lp system.

When provided with the substrate thiocyanate, Lp generates the biocidalcompound hypothiocyanite (OSCN⁻). Halides also act as substrate for Lp.Kussendrager and Hooijdonk (2000) state that oxidation of even smallamounts of I⁻ might be significant regarding antimicrobial actionbecause the LP—H₂O₂—SCN⁻ system is primarily bacteriostatic whereas theLP—H₂O₂—I⁻ system is bactericidal.

The Lactoperoxidase system has bacteriostatic or bactericidal activityon a variety of susceptible micro-organisms including bacteria, fungiand viruses.

Lp has been used for the preservation of raw milk during storage andtransportation, to extend the shelf-life of dairy products, as apreservative in cosmetics and pharmaceuticals. A number of oral hygieneproducts, such as mouthwashes and toothpaste containing Lp arecommercially available. Uses include wound treatment and opthalmicsolutions.

Immunoglobulins are an important component of milk and provide passiveprotection to the suckling young. Although they are not stronglycationic some immunoglobulins, IgG, IgM, IgA and polymericimmunoglobulin receptor (PIGR) are captured by cation exchange.Immunoglobulins are important in the first line of defence againstforeign invaders. Immunoglobulins bind to micro-organisms and thusopsonise them so that they are more easily recognized by phagocyticcells.

A number of proteins and peptides belonging to the ribonucleasesuperfamily have been identified in milk. Some of these have beenpurified and shown to have anti-viral and anti-microbial activity. Theyare variously described as RNase5, angiogenin 1, angiogenin 2 andlactogenin.

Angiogenin is a small polypeptide that is implicated in the formation ofnew blood vessels. Angiogenin is unique among the many proteins that areinvolved in angiogenesis in that it is also an enzyme with an amino acidsequence 33% identical to that of bovine pancreatic ribonuclease (RNaseA). Moreover, although Ang has the same general catalytic properties asRNase A—it cleaves preferentially on the 3′ side of pyrimidines andfollows a transphosphorylation/hydrolysis mechanism—its activity differsmarkedly both in magnitude and in specificity.

Although angiogenin contains counterparts for the key catalytic residuesof bovine pancreatic RNase A, it cleaves standard RNase substrates10⁵-10⁶ times less efficiently than does RNase A. Despite this apparentweakness, the enzymatic activity of Ang appears to be essential forbiological activity: replacements of important active site residuesinvariably diminish ribonuclease and angiogenesis activities inparallel, and a substitution that increases enzymatic activity alsoenhances angiogenic potency (http://en.wikipedia.orq/wiki/Angiogenin May2006).

The concentration in milk of a number of proteins and peptides increasesrapidly in response to trauma or infection. These are known as acutephase proteins (APP) and include lactoferrin, the ribonucleases,N-acetyl glucosaminidase, serum amyloid A, β Defensin and lysozyme.

Work in the dairy field on developing treatment or preventative uses ofLf and Lp have previously been focused towards obtaining more pure andconcentrated forms of these proteins from milk.

For example WO 03/002090 discloses the use of Lf, or pharmaceuticallyacceptable salts thereof to cows to provide a smooth transition of themammary gland from a lactation period to a dry period. WO 03/002090discloses the use of small volumes (preferably 100-250 mg/udder) of Lfin ointment or liquid form.

The use of extracted and purified Lf or Lp, or other milk components forthe treatment or prevention of mastitis require the extraction,isolation and purification of more concentrated and pure versions ofthese components.

Unfortunately extraction and purification methods can be time consuming,expensive and hard to develop and implement, especially on a largescale.

Also, the pure products are not fully effective in treating infection.

It is therefore desirable to have available a natural product which isquick and easy to produce which effectively prevents or treats bovinemastitis.

All references, including any patents or patent applications cited inthis specification are hereby incorporated by reference. No admission ismade that any reference constitutes prior art. The discussion of thereferences states what their authors assert, and the applicants reservethe right to challenge the accuracy and pertinency of the citeddocuments. It will be clearly understood that, although a number ofprior art publications are referred to herein, this reference does notconstitute an admission that any of these documents form part of thecommon general knowledge in the art, in New Zealand or in any othercountry.

It is acknowledged that the term ‘comprise’ may, under varyingjurisdictions, be attributed with either an exclusive or an inclusivemeaning. For the purpose of this specification, and unless otherwisenoted, the term ‘comprise’ shall have an inclusive meaning—i.e. that itwill be taken to mean an inclusion of not only the listed components itdirectly references, but also other non-specified components orelements. This rationale will also be used when the term ‘comprised’ or‘comprising’ is used in relation to one or more steps in a method orprocess.

It is an object of the present invention to address the foregoingproblems or at least to provide the public with a useful choice.

Further aspects and advantages of the present invention will becomeapparent from the ensuing description which is given by way of exampleonly.

DISCLOSURE OF INVENTION

According to one aspect of the present invention there is provided atreatment composition for treating or preventing bovine mastitis,

the treatment composition characterised in that it includes at least twocomponents which have an isoelectric point of or above substantially 6.8and is extracted from milk, or a milk derived substance.

Throughout this specification the treatment composition will be referredto as a cationic fraction.

Throughout this specification the term cationic fraction should be takenas meaning a fraction of milk, being cationic components that bind tocation exchange media. The cationic fraction should be taken to includeany component of milk which has an isoelectric point of or abovesubstantially 6.8.

In a preferred embodiment the treatment composition may be a cationicfraction which includes at least lactoferrin, lactoperoxidase andangiogenin.

In one preferred embodiment the cationic fraction may have the followingcharacteristics:

-   -   a molecular weight distribution of 3,000-80,000 Daltons by        SDS-PAGE,    -   isoelectric points of 6.8-11,    -   the main components are lactoferrin, lactoperoxidase and        angiogenin.

In a preferred embodiment, as well as the lactoferrin, lactoperoxidaseand angiogenin the cationic fraction may include a mixture of cationicpeptides.

In a preferred embodiment, as well as the lactoferrin, lactoperoxidaseand angiogenin the cationic fraction may include at least one of thefollowing: N-acetyl glucosaminidase, serum amyloid A, β Defensin orlysozyme.

In a preferred embodiment the cationic fraction shall be taken asmeaning an extract which contains a number of milk micro-components,specifically lactoferrin, lactoperoxidase, angiogenin, N-acetylglucosaminidase, serum amyloid A, β Defensin or lysozyme.

In a preferred embodiment the cationic fraction may also includelactoferricin, a fragment of lactoferrin that is claimed to be 10-1000times more anti-microbial than intact lactoferrin. In some embodimentsthe cationic fraction may undergo further processing to enhance thecontent or ratio of lactoferricin.

In a preferred embodiment the cationic fraction may also include CLP-1(chitinase-like protein), or at least one lysozyme-like component.

In a preferred embodiment the cationic fraction may also include atleast one immunoglobulin. Immunoglobulin(s) which could be expected tobe present may include type G, A, M, E or D immunoglobulin.

In a preferred embodiment the cationic fraction may include at least onemicro-component.

Throughout this specification the term micro-components should be takenas meaning bioactives with specific functionality. The most well-knownamong them are lactoferrin and lactoperoxidase, but a variety ofcationic proteins and peptides with biodefense properties also belong tothis group of micro-components.

It should be appreciated that many of the bioactives known to be presentin milk do not function alone but are interactive whereby one activityfacilitates or modulates the action of another.

It is anticipated that the cationic fraction may also include smallamounts of a number of growth factors; although these growth factors maybe present at low levels their action can be potent in stimulating cellrepair. These growth factors may include for example: EGF, IGF 1, TGF B1and TGF B2.

In a preferred embodiment the cationic fraction may also include anyother cationic compound of milk. Smolenski et al. (2007) have recentlyreported on the identity and significant number of minor proteins inbovine milk by Mass Spectrometry (MS) and, in particular, identified asignificant number of minor milk proteins that are involved in hostdefense. Their results are shown in Table 1. This also indicates (inbold) those which may be included in the cationic fraction of thepresent invention based on their isoelectric points. It should be notedthat Smolenski et al. (2007) used SDS-PAGE methods that would not detectlow concentration components, such as angiogenin, polymericimmunoglobulin receptor (PIGR) and growth factors.

Table 1. Host defense-related minor proteins identified from milk,showing those that may be extracted as part of the cationic fraction(bold) (reproduced from Smolenski et al., 2007)

TABLE 1 Minor proteins identified in bovine milk. ACC Number ProteinName Function pl NP_777250 cathelicidin 1 (Bactenecin antimicrobialproperties 6.8* 1) AAB64304 chitinase-like protein 1 eosinophilchemotactic properties 8.8 (CLP-1) Q290092 endoplasmin precursorparticipates in the assembly of antibody 4.7 (GRP94/GP96) molecules andsignalling molecule for polymorphonuclear neutrophils NP_776758 glucoseregulated protein 58 regulates signalling by interacting with unknownkDa stat3 NP_776770 heat shock 70 kDa protein 8 activated throughproinflammatory 5.4 response mechanisms enhancing MMP- 9 expression inmonocytic cells NP_071705 heat shock 70kDa protein 5 upregulation inmacrophages upon IL-4 unknown (glucose-regulated protein) stimulationAAA18337 heat shock protein 27 inhibitor of neutrophil apoptosis 5.98*BAA32525 heat shock protein 70 kDa stress response (refolding and 5.68*protein 1A degradation of denatured proteins) AAC98391 immunoglobulinIgA antigen recognition X¹ AAN07166 immunoglobulin IgD antigenrecognition X¹ AAB37381 immunoglobulin IgG antigen recognition X¹AAN60017 immunoglobulin IgM antigen recognition X¹ AAQ88452 IRTA2 B-cellimmunoglobulin super-family unknown receptor AAA30617 lactoferrin ironbinding and antimicrobial 8.67* peptide “lactoferricin” NP_776358lactoperoxidase oxidative peroxidase activity 8.327* BAA07085 lymphocytecytosolic protein regulation of neutrophil integrin function 5.21* 1(65K macrophage protein/L-plastin) P21758 macrophage scavenger mediatethe binding, internalization and 5.7* processing of negatively chargedmacromolecules AAA36383 nucleobindin 1 promotes production ofDNA-speicific 5.05* antibodies NP_776998 peptidoglycan recognitioninnate immunity pattern recognition 9.38* protein molecule XP_611685S100 calcium binding associated with S100A8 and implicated 6.29* proteinA9 (calgranulin B) in inflammatory response XP_593653 S100 calciumbinding upregulation associated with 6.7 protein A11 (calgizzarin)proinflammatory response NP_777076 S100 calcium binding antimicrobialpeptide “calcitermin” 5.9 protein A12 (calgranulin C) P42819 serumamyloid A protein involved in acute phase cytokine 6.94 signalingCAA67117 xanthine dehydrogenase superoxide anion, hydrogen oxide 8.0 andperoxxynitrite production ¹Immunoglobulins typically have isoelectricpoints the range of 5.0-9.5. As such, not all bind to the cationicexchange resin. *The isoelectric points of these proteins have beencalculated based on the expected protein structure. (Swiss Prot/TrEMBL,www.expasy.org).

Some of the cationic fraction components (e.g lactoferrin, angiogenin)may also have minor variants,—such as variations in amino acid sequenceor in degree and type of glycosylation, these minor variants, and theirpresence in the cationic fraction should also be taken as being coveredby the present application.

According to a second aspect of the present invention there is provideda method of treating or preventing bovine mastitis using a treatmentcompound substantially as described above, the method characterised bythe step of applying the treatment compound onto or into at least onebovine teat.

Throughout this specification the term mastitis should be taken toinclude both clinical and sub-clinical mastitis. The term mastitisshould also be taken to include bacterial, microbial or any other formof mastitis.

It has long been known that at involution (cessation of milking, dryingoff) there is increased production of the defense proteins which havestrong antimicrobial and antiviral activity, immunomodulatory, and cellgrowth and repair activities.

During intra-mammary infection or trauma, and involution (cessation ofmilking, drying off) secretion of the minor defense or regulatoryproteins is enhanced (Reiter and Oran, 1967; Schanbacher and Smith,1975: Talhouk et al., 1996).

The milk lipids (Isaacs et al., 1995) and glycolipids (Newburg, 1996)and sphingolipids (Dillehay et al., 1994: Merrill et al., 1995) alsocontribute to skin repair and the defense against microbial and viralpathogens. The lipid component of the keratin plug which forms in theteat canal also has antimicrobial properties.

It is well known that lactoferrin, lactoperoxidase, angiogenin, (RNase),N-acetyl glucosaminidase, serum amyloid A, β Defensin and lysozyme areall part of the innate defense system. They play an important part ofthe natural host defense system against invading micro-organisms,protecting the eyes, the upper respiratory tract, the lactating mammarygland and the intestinal tract of the new born infant.

In a preferred embodiment the cationic fraction extracted from wholemilk has the main proteins and growth factors as shown in Tables 2 and3.

TABLE 2 Sub-fractions from the cationic fraction principal components,as identified by Mass Spectrometry (MS). Total Protein Identity from MS(mg/ml) % of total estimated purity (%) lactoperoxidase¹ 4.2  8.0% 95%quiescin 1.6  3.0% 50% jacalin-like protein 1.4  2.7% 60% chitinase-likeprotein 0.4  0.8% 80% angiogenin 10.0 19.0% 60% lactoferrin 35.0 66.5%95%

TABLE 3 Enzyme-linked Immunsorbent Assay (ELISA) measurement of growthfactors in the cationic fraction. TGFB1 TGFB2 Fraction (ng/mg) (ng/mg)IGF1 (ng/mg) IGF2 (ng/mg) angiogenin fraction 2.0 14.5 2.2 4.7lactoperoxidase fraction 7.0 109.0 4.0 5.0

From the above tables, the ratios of the three major components,lactoferrin, lactoperoxidase and angiogenin, are 6.2:1.2:1. This is atypical ratio of these main components, but is indicative only.

The innate immune system is the first line of defense against infection,and is up-regulated in response to inflammatory stimuli.

The characteristics of innate immunity include: broad spectrum(non-specific) and lack of memory.

The applicants believe that the cationic fraction of the presentinvention has a number of modes of action, which act together to form avery effective treatment composition. The cationic fraction hasinhibitory (bacteriostatic), bactericidal and immune boosting effects.The synergistic action between sub-components also increases the actionof the fraction, in particular in comparison with purified individualsub-components. Similarly, synergistic action between the fraction andthe natural immune response can again increase its effectiveness, byopsonising bacterial cells to make them more recognizable byphagoocytes.

It is well known that bovine mastitis (and other forms of mastitis) area result of infection by a number of differing bacterial species (orother microbial species). It is envisioned that the effectiveness of thepresent invention to treat mastitis also comes from the action ofdifferent sub-components of the fraction acting on different infectingspecies.

For an in vivo antimicrobial, the basis for antimicrobial action couldbe said to have two primary mechanisms of potential efficacy:

(1) direct effect of antimicrobial on pathogens, and

(2) immune-boosting activity on the target.

The scientific basis of this hypothesis, however, is as follows. Thecharacteristics of innate immunity in an animal are:

-   -   (i) broad spectrum (non-specific)    -   (ii) lack of memory for specific pathogens.

While an enormous number of antimicrobial peptides with diversesequences have been identified in mammalian systems, a common feature isa cationic amphipathic structure. This structural motif gives rise to apropensity to bind to microbial lipids and disrupt membranes. But thatmembrane permeabilisation is not always sufficient to cause cell death.However, the synergistic action of a cationic peptide and an agent thatacts on the cytoplasm to cause cell death may be bactericidal.

A fraction for milk including a range of the above proteins haspreviously been extracted and used for the treatment and prevention ofperiodontal diseases. For example, U.S. Pat. No. 6,544,498 whichdiscloses the extraction by gradient elusion of a basic protein fractionwhich has an isoelectric point between 7.5 and 11 and a molecular weightdistribution of 3,000 to 80,000 Daltons. A broad fraction has also beenused for the treatment of osteo problems (U.S. Pat. No. 5,976,597).However, this fraction was limited to 2,000 to 24,000 Dalton, whichwould eliminate lactoferrin and lactoperoxidase from the fraction.Additionally, this fraction required post-processing to be effective.

Mastitis is very different from periodontal disease, for which U.S. Pat.No. 6,544,498 describes the use of a similar fraction. It would not beobvious to one skilled in the art to use the fraction of U.S. Pat. No.6,544,498 to treat bovine mastitis due to the significant differencesbetween these conditions:

-   -   Periodontal disease occurs in the mouth, affecting the teeth and        gums, where infection occurs on external surfaces. This is a        very different environment to the mammary gland which is        affected by mastitis on the internal tissue surfaces of the        alveoli, ducts and cisterns.    -   Periodontal disease leads to loss of alveolar bone. This is        irreversible, therefore requiring a preventative or ameliorative        treatment. This is again, in direct contrast to mastitis, which        leads to reversible tissue damage in the mammary gland, if        detected soon enough after onset. For mastitis, preventative or        ameliorative treatments are generally not practical, due to the        large number of animals to be treated, the manual labor        requirements and cost.    -   In periodontal disease bacterial entrance and colonization        occurs via and within the oral cavity. In contrast, for mastitis        cases, bacterial entrance and colonization occurs via the teat        canal. In mastitis cases bacterial colonization is aided by a        constant rich biological medium—milk.    -   U.S. Pat. No. 6,544,498 specifically states in the background        art section (paragraph 2) that the conventional treatment using        antibacterial mouthwashes has low effectiveness. This indicates        that the use of a general antibacterial compound will not be        effective. U.S. Pat. No. 6,544,498 argues that the inventiveness        of their application is based on the fraction curbing the        decrease in alveolar bone and shows experimental data supporting        this.

The disclosure in U.S. Pat. No. 6,544,498 discusses a basic proteinfraction which has the main components being lactoperoxidase andlactoferrin. It is disclosed that a daily dose of 1-50 mg per day, of acomposition having a fraction content of 0.1-1.0% will be effective atpreventing periodontal disease.

U.S. Pat. No. 6,544,498 however, does not disclose the requirement fordetection or diagnosis prior to treatment, that the fraction has anyantimicrobial or other action (besides periodontal disease), or themechanism of action (either direct or immune boosting) and does notteach, mention, discuss or show that there are synergistic effectsbetween the individual sub components, as there are for the cationicfraction of the present invention.

The advantages of the present invention over that in U.S. Pat. No.6,544,498 include the following:

-   -   Treatment of mastitis preferably requires the synergistic effect        of all proteins in the fraction, rather than just the three        major components.    -   It is thought by the applicant that treatment of mastitis        combines both a direct antimicrobial effect with an        immune-boosting effect, including a synergistic effect with the        natural immune response.    -   The cationic fraction of the present invention is extracted from        milk from the mammary glands, concentrated and used to treat the        same organ (i.e. mammary glands) from which it was extracted.        This is highly beneficial as it provides a much more natural        treatment. This is not practical for oral applications.    -   In preferred embodiments the cationic fraction of the present        invention may be used on the same animal species from which it        is extracted. Again, this provides a more species specific        treatment, with components which are not going to be considered        ‘foreign’. Again, this is not practical with human oral        applications.    -   Daily preventative dosages of the cationic fraction for treating        mastitis are not required. Instead, treatment on diagnosis of        the condition is utilized.

Despite the industry moving towards more pure forms of milk components,such as lactoferrin for the prevention and treatment of bovine mastitis,the applicant has found that the above components in the innate defensesystem may not act individually as anti-inflammatory and antimicrobialagents against the range of mastitis producing organisms.

The discovery of the effectiveness of the cationic fraction of thepresent invention against the micro-organisms which cause orcharacterize mastitis was made during studies in the advantages in usingbioactive fractions extracted on farm versus factory processed milkbioactives. One of the key advantages of bioactives such as lactoferrin(Lf) and lactoperoxidase (Lp), is their anti-microbial activity.Therefore, the applicant set up trials to establish suitable bioassaysfor characterizing the bioactivities using common pathogens. One ofthose pathogens was Streptococcus uberis.

Interestingly, the applicant found that the inhibitory effects againstthe pathogen diminished as the cationic bioactive fractions became morepurified. This was contrary to common thinking as it is commonlyunderstood that the purer a component is, the more effective it will be.

Considering the origins of these bioactives in cows' milk, the applicantbelieves they are produced in response to immune challenges within thegland. If there are key biochemical pathways leading to immune successwithin the mammary gland, there would be synergistic actions between thediscrete bioactives, which actually leads to a successful immuneresponse. That is to say, purification of individual parts of thecationic fraction may not be the key to a successful naturally-derivedinhibitory product. This led to the hypothesis, which was subsequentlytested that the ‘total cationic fraction’ of the present invention couldbe used as a successful naturally-derived inhibitory product.

In a preferred embodiment the cationic fraction may be extracted fromwhole milk. However, this should not be seen as limiting as the termmilk should be taken to include whole milk, skim milk or whey.

It is well known that many conditions affect lactoferrin concentration,such as once or twice daily milking, stress, age, breed, feed types andmilking interval. It is anticipated that these factors may also effectthe concentration of components within the cationic fraction, or thefraction itself.

It is also well known that many milk components are increased incolostrum. Although the cationic fraction of the present invention maybe extracted from colostrums it is anticipated that this will not be themain source for the following reasons: firstly there is only a shortperiod of time when colostrum is produced, and secondly colostrum ismore difficult to process through most extraction media, for examplecation exchange media.

It should be appreciated that the term milk may include any raw (orunprocessed) milk. This is taken to include raw milk which has beenchilled, incubated, or stored, at either a chilled or ambienttemperature.

Throughout this specification the term ‘milk derived substance’ shouldbe taken as meaning any pre-processed milk, i.e. not raw (orunprocessed) milk. It should be appreciated that processing may includea number of standard or unique processing procedures such ascentrifugation, pasteurisation, acidification, or any other standarddairy factory or processing techniques.

The term ‘milk derived substance’ should also be taken to include anypost-processing techniques. For example, freeze-drying, solid productforms and liquid product forms.

In one preferred embodiment the cationic fraction may be extracted frombovine milk.

However, this should not be seen as limiting, as the cationic fractionmay also be extracted from other mammalian species, including, but notlimited to sheep, goats, buffalo, camels and humans.

In one embodiment the proportions of the different cationic componentswithin the cationic fraction may be as extracted, or concentrated.

However, this should not be seen as limiting, as it may be desirable toalter or control the ratio of at least one, or a number of componentsrespectively. It should be appreciated that any such alteration in theproportions of the cationic fraction components are covered by thisdisclosure.

In one preferred embodiment the cationic fraction may be extracted“on-farm”, during or directly after the milking process. This may beadvantageous as some of the components may be lost, damaged or denaturedduring subsequent handling, storage, fat removal, or other processingsteps.

However, this should not be seen as limiting as the cationic fraction ofthe present invention may also be extracted once the milk has beencollected on farm, or after the milk has left the farm during anyfurther storage, transport or processing step.

In the case of the cationic fraction being extracted from milk that isprocessed in the usual manner involving storage, transport andconversion to skim milk or whey the temperature should preferably bemaintained at substantially 4-7° C. to minimize microbial growth.

In the case of the cationic fraction being extracted from whole milk thetemperature should preferably be maintained at not less than 35 C toensure that lipids remain in a liquid state so that they can easily passthrough the extraction material. And to ensure the bioactivity of thefactors in the cationic fraction are maintained at or close to theendogenous state.

In an alternative embodiment the cationic fraction may be extracted fromgenetically modified animals, for example genetically modifiedenhancement of lactoferrin production in dairy cows. One skilled in theart would realise that extraction from the milk of genetically modifiedanimals may affect the ratio or concentrations of lactoferrin, or othercomponents in the cationic fraction, or a whole cascade of keycomponents.

In one preferred embodiment the cationic fraction may be extracted fromthe same species of animal that the treatment substance is intended tobe used on. For example a cationic fraction extracted from cow milk totreat/prevent bovine mastitis, or a cationic fraction extracted fromgoat milk to treat mastitis in goats.

In a preferred embodiment the final product or cationic fraction may beused for the treatment or prevention of bovine mastitis.

One major advantage of the use of the cationic fraction of the presentinvention in the prevention or treatment of bovine mastitis is that itis from milk and is therefore considered to be natural and safe to use.

The cationic fraction of the present invention does not have awithholding period as antibiotics, or many other treatments do, andcannot contaminate the milk, as antibiotics can, for example when thecow has been treated and recovered from mastitis but may still havetraces of antibiotics in the milk.

In a preferred embodiment the cationic fraction may be used to form partof a final treatment composition, and shall be referred to as suchherein. However this should not be seen as limiting as in some instancesthe cationic fraction alone may be administered for the prevention andtreatment of bovine mastitis.

The final composition may also include other compounds which may includeantibiotics and analgesics.

For use in a milking cow the cationic fraction may preferably beincorporated with an aqueous solution, such as a buffer. This moredilute form could be prepared from a concentrate, which was made from aconcentration step, for example, by ultrafiltration.

In one preferred embodiment the final treatment composition may be inthe form of a liquid.

This may include for example: teat sprays, teat wipes, udder/teatwashes, milking cluster backflush solutions or intramammary formulationsfor either lactating or non-lactating animals.

Liquid treatments for use in a milking cow may be massaged or applied upinto the udder after milking.

However this should not be seen as limiting, as the final treatmentcomposition could also be in the form of an oil, an emulsion, a powder,a gel or cream or as a solid putty like material.

In an alternative embodiment the final composition may be in the form ofa teat seal. One skilled in the art would realize that the teat sealformulation may be in a range of configurations, for example, it maysolidify after application, or may in a more solid form. The teat sealtype of treatment is typically applied near or within the teat canalentrance.

Currently, it is anticipated that the dosage regime of the compositionof the present invention may be within the range of 1 g/day in a 10 mldose once a day for three days. This relates to 1 g of total protein,made up to the 10 ml dose in a pharmaceutically acceptable carrier orbuffer, for example Ringer's salts.

Throughout this specification the term final treatment compositionshould be taken as meaning the form in which the cationic fraction isadministered to the animal.

The final treatment composition may include at least one or more of thefollowing:

carriers, buffers, preservatives, excipients or other pharmaceuticallyacceptable components required to ensure the cationic fraction is in aform that is easily dispensed, used and is efficient for the purpose ofpreventing and treating mastitis.

In one embodiment the final treatment composition may also include atleast one component which is capable of controlling the time release ofthe composition. This may be used to effectively treat mastitis over anextended period of time. Known components which could be used for thispurpose would be well known to one skilled in the art.

In a preferred embodiment the cationic fraction may be provided in thefinal treatment composition in a concentration range of 2-20% (w/w).This concentration is believed to provide the greatest ease inapplication with respect to the volume being injected into the teat. Itshould be appreciated that this may differ substantially based on theapplication method or volume being used.

In a preferred embodiment the cationic fraction may be mixed with aninert liquid carrier.

In the embodiment where the final treatment composition is for use as ateat seal the final composition may also incorporate any ‘hardening’component added to block the teat canal and physically prevent microbesfrom entering same. In some instances the final treatment compositionconfigured for use as a teat seal may become substantially more solidwhen placed in the teat canal, thereby also physically preventing theentry of micro organisms.

In a preferred embodiment the cationic fraction of the present inventionmay be used to treat cows during the drying off or dry period.

In an alternative embodiment the cationic fraction may be utilizedduring the milking or lactation period. In this instance it ispreferable that the cationic fraction, or final product containing thefraction is in a liquid form as it is undesirable to block teats duringthe milking period.

According to another aspect of the present invention there is provided atreatment formulation which includes,

a treatment composition extracted from milk, or a milk derivedsubstance, wherein the fraction contains at least two components with anisoelectric point of or greater than substantially 6.8, and

a cell lysing substance.

In a preferred embodiment the treatment formulation may be anantimicrobial.

In a preferred embodiment the treatment formulation may also include oneor more of the following:

-   -   1. a peroxidase substrate, and/or    -   2. hydrogen peroxide or a source of hydrogen peroxide.

In a preferred embodiment the treatment substance may be the cationicfraction substantially as previously described. This includedlactoferrin, lactoperoxidase and angiogenin as its main components.

In a preferred embodiment the cell-lysing substance may be anycompatible compound, or combination of compounds that are capable offully, or partially lysing the cell wall.

In one embodiment the cell lysing substance may be a detergent-likesubstance.

In one preferred embodiment the cell lysing substance may be amonoglyceride.

In one preferred embodiment the monoglyceride may be monolaurylglycerol.

Monolauryl glycerol is a monoglyceride consisting of lauric acidcovalently bonded to a glycerol molecule through an ester linkage.Lauric acid is believed to have the highest cell lysing action of any ofthe fatty acids which could potentially be incorporated into themonoglyceride.

However, it should be appreciated that any other monoglyceride—i.e. witha different fatty acid chain may also be utilized, as long as this hassome cell lysing action

In a preferred embodiment the peroxidase substrate may be any substrateor compound on which lactoperoxidase or any other peroxidase enzymes mayact.

In one preferred embodiment the peroxidase substrate may be thiocyanate.

In one particular preferred embodiment the peroxidase substrate may bepotassium or sodium thiocyanate. Alternatively any other thiocyanatewhich can act as a peroxidase substrate may be utilized.

In a preferred embodiment the minimum concentration of peroxidasesubstrate is 20 ppm (when the peroxidase substrate is sodiumthiocyanate), 20 ppm (when the source of hydrogen peroxide is ascorbate)and 5 ppm (when the cell lysing agent is monolauryl glycerol) (as shownin vitro).

However, one skilled in the art would realize that these may differdepending on the type of composition being applied, i.e. a liquid or apaste and the specific site of application or action.

One skilled in the art would also realize that in vivo, the site ofapplication may already have peroxidase substrate present. In this caseit may not be required to be included in the formulation, or may be ableto be included at a lower concentration.

In a preferred embodiment the source of hydrogen peroxide used may beascorbate or ascorbic acid.

Ascorbate and ascorbic acid have been shown in previous publications tobe good substrates for peroxidase enzymes. This is a preferred source ofhydrogen peroxide as it is stable—unlike peroxide itself.

Hydrogen peroxide is also a substrate of peroxidase enzymes. Therefore,one skilled in the art would realize that the same considerations wouldapply as discussed above in relation to the peroxidase substrate.

Substrate (in the form of hydrogen peroxide or another substrate) ispreferably included for lactoperoxidase only. Lactoperoxidase is theonly one of the major components of the cationic fraction which is anenzyme. A substrate is required for lactoperoxidase (unless alreadypresent) in order to convert thiocyanate to a biocidal compound.

It will be appreciated that the cationic fraction may contain otherenzymes, and that substrate for same may be incorporated into thecomposition to increase efficiency.

In a preferred embodiment the formulation containing additives may beused for dairy purposes as discussed above in relation to the cationicfraction alone.

However, this should not be seen as limiting as the formulationcontaining additives has a general antimicrobial action, and could beused for a wide number of additional applications. These include forexample: soaps, cleaning agents, food-grade coatings, wound/ulcer/coldsore dressings or topical treatments to name a few. One skilled in theart would readily realize that the formulation with additives could beused in any application where a general antimicrobial agent is required.

The applicant has found, as shown in the best modes method section that,in vitro, the cationic fraction with the addition of thiocyanate andascorbate (i.e. a peroxidase substrate and a source of hydrogenperoxide) has significantly greater action against a range of bacterialspecies than the isolated individual components of the fraction.

According to another aspect of the present invention there is provided amethod of extracting a treatment compound substantially as describedabove from milk, including the steps of:

-   -   a) passing milk through an extraction material, and    -   b) eluting a fraction of the bound milk components        -   wherein parameters of the extraction process provides a            cationic fraction which includes at least lactoferrin,            lactoperoxidase and angiogenin,

the method characterised in that the step b) is conducted once.

In a preferred embodiment the extraction material may be a cationexchange material. This may either be in the form of resin, expanded bedresin, magnetic beads, membrane or other suitable form for large scaleextraction.

In a preferred embodiment the cation exchange material may be anymaterial that has sufficient mechanical strength to resist highpressures and maintain high flow rates.

In a preferred embodiment the cation exchange resin may have a meanparticle size in excess of 100 μm. Resins in larger bead form have beendeveloped for use with viscous feed streams because they do not pack asclosely as smaller beads therefore there are wider channels so thatthere is not excessive back-pressure.

Examples of suitable cation exchange resins are SP-Sepharose Big Beads,SP-Sepharose Fast Flow, SP-Toyopearl and S-Ceramic HyperD.

One example of an extraction and purification process is as follows:

Lactoferrin binds firmly to cation exchange and is the last majorprotein to elute in a salt gradient. Therefore a single step elutionwith 1M salt (80 mS-100 mS) elutes all proteins and peptides in a singlefraction (cationic fraction). Elution with 80-100 mS salt following aprior 40 mS elution will yield a fraction that is primarily lactoferrin.

After lactoferrin, lactoperoxidase is the next most abundant of thecationic proteins captured by ion exchange from milk (0.03-0.075 mg/mlmilk). In a salt gradient lactoperoxidase elutes from cation exchangebefore lactoferrin at 25-30 mS.

The growth factors EGF, IGF 1, !GF 2, TGF B1 and TGF B2 are present inmilk in ng/ml quantities, and have been shown to be captured by cationexchange.

A number of other biologically active cationic peptides elute betweenlactoperoxidase and lactoferrin at 35-40 mS (intermediate fraction).Therefore the concentration of salt used at each step in the elutiondetermines whether these biologically active peptides are in thelactoperoxidase fraction or the lactoferrin fraction.

Immunoglobulins are eluted in low salt (15-20 mS).

In a preferred embodiment the milk, or milk product may be passedthrough a membrane having cationic exchange properties, or a columnpacked with the cationic exchange resin or a batch reactor withsuspended cationic resin, whereby the micro-components adsorb from thestarting milk or product thereof onto the cationic exchange resin ormembrane.

After adsorption of milk micro-components the cationic fraction ispreferably extracted by elution with a salt solution.

However, this should not be seen as limiting as elution of the cationicfraction may also be via a shift in pH. This method, however, is notpopular in large scale commercial processes as the high pH required toremove lactoferrin from the resin could be damaging to the lactoferrin,or in the present case any other components in the cationic fraction.

In a preferred embodiment, before elution, the resin or membrane may berinsed with a salt solution. Preferably the rinse solution may be sodiumchloride or sodium bicarbonate, with conductivity between 5 and 10 mS(millisiemens/cm). This rinse step ensures that substantially allnon-adsorbed milk components are rinsed off the resin or out of themembrane.

In a preferred embodiment the cationic fraction may be eluted in a saltgradient between substantially 10 mS and 100 mS conductivity (0.1 to 2.0M salt).

In a preferred embodiment the cationic fraction may be eluted in asingle fraction by passing a salt solution with conductivity between 80and 100 mS through the column or membrane.

In a preferred embodiment the elution salt may preferably be sodiumchloride. However, this should not be seen as limiting as other saltsincluding sodium acetate, sodium bicarbonate, ammonium bicarbonate, orpotassium chloride may be used.

Having the cationic fraction eluted in a one-step elution provides asignificant advantage. It decreases the length of extraction timethereby decreasing the possibility of bioactives being denatured. Italso decreases the time, labour and cost of the extraction process. Thiscan provide a significant advantage, especially on a large scale.

In a preferred embodiment after initial monitoring of the protein levelsin the eluted stream to determine the concentration of salt and thevolumes required to elute all the protein, the typical large scaleprocess operates on volumes rather than continuous monitoring.

In a preferred embodiment the extraction may be undertaken in acontinuous manner.

In another preferred embodiment, the extraction may be undertaken in abatch elution.

In the above preferred embodiments the cationic fraction may beextracted by a ‘one-step’ process, by step elution.

In an alternative embodiment the cationic fraction may be extractedusing a gradient elution.

However this should not be seen as limiting as the cationic fraction mayalso be extracted in independent fractions and recombined to form thecomplete cationic fraction at a later stage.

In some embodiments the cationic fraction may undergo furthertreatments, by standard techniques known in the art, for example, toremove salt, or to concentrate, or to filter for sterility or to removeendotoxin. The concentrated fraction may also be lyophilised.

In a preferred embodiment the cationic fraction may be concentrated toapproximately 20% solids.

The present invention has a number of significant advantages over priormethods of preventing and/or treating bovine mastitis, these include thefollowing:

-   -   Having the cationic fraction eluted in a one-step elution        decreases the length of extraction time required for extraction,        thereby decreasing the possibility of bloactives being        denatured. It also decreases the time, labour and cost of the        extraction process. This can provide a significant advantage,        especially on a large scale.    -   The cationic fraction of the present invention is from milk and        is therefore considered to be natural and safe to use.    -   The cationic fraction of the present invention does not have a        withholding period as antibiotics, or many other treatments do,        and cannot contaminate the milk or meat, as antibiotics can, for        example when the cow has been treated and recovered from        mastitis but may still have traces of antibiotics in the milk or        meat.    -   It is more effective for the prevention and treatment of bovine        mastitis than each individual component alone.    -   Provides a non-antibiotic treatment option for organic farmers.    -   Provides a non-antibiotic treatment for those concerned that the        wide-spread use of antibiotics in animal treatments is        contributing to an increase in the incidence of antibiotic        resistance in bacteria.    -   Mastitis occurs in the mammary gland which is a unique and        specific environment. Mastitis is caused by a wide range of        pathogens making it difficult to treat with a single compound.        The formulation overcomes this problem and is active against a        number of mastitis (and other) pathogenic species.    -   The formulation of the present invention can be extracted from        the organ and species on which it is to be used—making it more        specific.    -   It can be administered once mastitis has been diagnosed.    -   Provides a synergistic effect between a number of components        within the cationic fraction—again including efficiency and        activity.    -   Provide a direct antimicrobial and anti-inflammatory effect as        well as an immune boosting effect.

BRIEF DESCRIPTION OF DRAWINGS

Further aspects of the present invention will become apparent from thefollowing description which is given by way of example only and withreference to the accompanying drawings in which:

FIG. 1 shows the general elution profile of all the fractions fromcation exchange

FIG. 2 shows the fractions separated on SDS_PAGE, and indicates the bandthat was excised for Mass Spectroscopy and identified as bovineangiogenin,

FIG. 3 shows a radial diffusion assay plate, for_(—) Streptococcusuberis,

FIG. 4 shows a radial diffusion assay plate, for Staphylococcus aureus,

FIG. 5 shows a graph of Escherichia coil inhibition using the cationicfraction alone, and with 40 ppm of sodium thiocyanate,

FIG. 6 shows a graph of Streptococcus uberis inhibition using thecationic fraction alone, and with 75 ppm of sodium thiocyanate and 150ppm of ascorbate,

FIG. 7 shows a graph of Streptococcus uberis growth using variousub-fractions of the cationic fraction, a recombined cationic fractionand an unfractionated (whole) cationic fraction,

FIG. 8 shows a graph of Escherichia coil growth using varioussub-fractions of the cationic fraction, a recombined cationic fractionand an unfractionated (whole) cationic fraction,

FIG. 9 shows a graph of Staphylococcus aureus growth using varioussub-fractions of the cationic fraction, a recombined cationic fractionand an unfractionated (whole) cationic fraction,

FIG. 10 shows a graph of the effect of the cationic fraction on thegrowth of Streptococcus uberis in full cream milk,

FIG. 11 shows a graph of the effect of the cationic fraction on thegrowth of Escherichia coil in nutrient media in a microtitre plate,

FIG. 12 shows a graph of the effect of the cationic fraction on thegrowth of Staphylococcus aureus in nutrient media in a microtitre plate.

BEST MODES FOR CARRYING OUT THE INVENTION

FIG. 1 shows the elution profile of the cationic fraction from cationexchange. This represents all the protein peaks (as detected at 280 nm)that would be present in a single fraction eluted in a gradient from80-100 mS. The main components in the cationic fraction areimmunoglogulin, lactoperoxidase, lactoferrin, and a group of minorcomponents that include angiogenin.

FIG. 2 shows the main fractions separated on SDS-PAGE, and indicates theband that was excised for Mass Spectroscopy and identified as bovineangiogenin.

The immunoglobulin fraction shows PIGR (76 kDa) as the predominant band,and the heavy (52 kDa) and light chains of immunoglobulin.

The Lp fraction is mainly lactoperoxidase with a small amounts of heavyand light chains of immunoglobulin and angiogenin.

The intermediate fraction has a prominent band of lactoperoxidase andlactoferrin (80 kDa) and a band at around 15 kDa that was identified byMass Spectrometry as angiogenin, a band at approximately 13 kDa that wasidentified by Mass Spectrometry as jacalin-like.

The Lf fraction is predominantly lactoferrin (80 kDa).

Experimentation Undertaken:

To test the hypothesis that the cationic fraction could be used as asuccessful naturally-derived inhibitory product, a variety of in vitroexperiments have been conducted on the inhibitory effect of the cationicfractions captured from milk by cation exchange. These experiments havebeen summarized into several areas.

-   -   1. Radial Diffusion (RD) agar assays    -   2. Minimum Inhibitory Concentration (MIC) assays in microtitre        plates

The applicant has also tested various cationic sub-fractions versus thetotal cationic fraction to determine inhibition efficacy against thethree most common major mastitis-causing pathogens: Streptococcusuberis, Staphylococcus aureus and Escherichia coli.

The applicants have also aimed to form a formulation that is effectiveagainst all three pathogens. Since the activity of the fraction waslower against certain pathogens, the applicant has also explored variousadditives to the formulation to achieve this ‘one formulation’ goal.

1. Extraction of the Cation Fraction

The process of producing the cationic fraction involved fractionatingmilk through a cation exchange resin, eluting the bound components fromthe resin using a salt solution, which can be either a one-step highmolarity (>1M) salt or a gradient elution from a lower molarity up toover 1M, collecting the eluted components in a single fraction, and thendesalting and purifying the collected fraction.

The cationic fraction was analysed for its constituent components, andthe results shown in Tables 2 and 3 (reproduced below). Table 2 shows atypical result for yield and identity of the major proteins identifiedin the cationic protein fraction.

This particular cationic fraction was captured from raw, whole milk.Growth factors, TGFB 1, TGFB 2, IGF1 and IGF2 are present in lowamounts, and are detectable by ELISA in freeze dried concentrates (Table3).

TABLE 2 Sub-fractions from the cationic fraction, as measured by MassSpectrometry (MS). (¹Lactoperoxidase was determined via extinctioncoefficient rather than MS.) Total Protein Identity from MS (mg/m1) % oftotal estimated purity (%) lactoperoxidase¹ 4.2 8.0% 95% quiescin 1.63.0% 50% jacalin-like protein 1.4 2.7% 60% chitinase-like protein 0.40.8% 80% angiogenin 10.0 19.0% 60% lactoferrin 35.0 66.5% 95%

TABLE 3 Enzyme-linked Immunsorbent Assay (ELISA) measurement of growthfactors in the cationic fraction TGFB1 TGFB2 Fraction (ng/mg) (ng/mg)IGF1 (ng/mg) IGF2 (ng/mg) angiogenin fraction 2.0 14.5 2.2 4.7lactoperoxidase fraction 7.0 109.0 4.0 5.0

2 Radial Diffusion Assay

Methodology

-   -   Growth medium (appropriate for the selected organism) was        inoculated with a fresh culture of the organism and poured in a        thin layer into a petri dish.    -   When the agar set, wells were cut (with a sterile cork borer),        the agar plug was removed, and each well was filled with a test        sample.    -   The petri dishes were incubated overnight (at the temperature        appropriate for the organism).    -   If the test sample has inhibited the growth of the organism,        clear zones with no growth were observed around the wells.

Results Summary

FIG. 3 shows a radial diffusion assay plate for Streptococcus uberis. Inthis experiment, the goal was to test various additives into theformulation, isolating the additives' effect from the cationicfraction's effects. On this plate, the sources were (1) whole cationicfraction (20-40 mg/ml) with sodium thiocyanate (500 ppm) andmonoglyceride (250 ppm) and (2) sodium thiocyanate (500 ppm) andmonoglyceride (250 ppm) alone. The total formulation is shown in fourspots starting clockwise from the ‘12 o'clock’ position. The additivesalone spot is in the 10 o'clock position. Consistently large and clearzones for the total formulation can be seen, while no inhibition fromthe additives alone was observed.

FIG. 4 shows a radial diffusion assay plate tested againstStaphylococcus aureus. In this experiment, various combinations of thecationic fraction with and without the additives, sodium thiocyanate(500 ppm) and monoglyceride (250 ppm), were used. While the inhibitoryeffects were less than those against Streptococcus uberis, one can seethat the cationic fraction alone (3 o'clock position) and the totalformulation (6 o'clock position) resulted in inhibitory zones. Theadditives alone (12 o'clock position) and the cationic fraction withsodium thiocyanate (9 o'clock position) achieved no inhibition,suggesting that the monoglyceride is a key component for the formulationagainst Staphylococcus aureus.

3 Minimum Inhibitory Concentration (MIC) Assays

Assays in microtitre plates, while more time consuming, allow a greaterrange of dilutions of sample and additives to be tested. Also samplescan be taken from the wells with no growth to determine whether theorganisms have been killed or merely inhibited.

Methodology

-   -   Dilutions of the test sample plus various additives were placed        in the wells of a microtitre plate.    -   A small inoculum of the bacterial culture was added to each        well.    -   The plate was incubated at the appropriate temperature.    -   A spectrophotometric microtitre plate reader was used to measure        the turbidity (absorbance at 450 nm) in each of 96 wells every        30 minutes for 18 hours.

Results Summary

In graphical form, FIG. 5 shows the extent of growth of the Escherichiacoli indicated by the height of the bars. The shortest bars show maximuminhibition of growth. For this figure, the left-hand bars indicate thatsome inhibition of growth is achieved with the cationic fraction aloneat a concentration of 1 mg/ml. However, adding 40 ppm of sodiumthiocyanate to the cationic fraction allowed total growth inhibition tooccur at a cationic fraction concentration of 2 mg/ml. This indicatesthat lactoperoxidase contributes to the antimicrobial activity when itssubstrate (thiocyanate) is included.

FIG. 6 shows the results of a different formulation of the cationicfraction against Streptococcus uberis, this time using sodiumthiocyanate (75 ppm) and ascorbate (150 ppm). Against Streptococcusuberis, there is no inhibition in vitro using the cationic fractionalone up to 0.8 mg/ml. However, adding sodium thiocyanate and ascorbateshows an inhibitory effect occurring as low as 0.2 mg/ml of the cationicfraction. This confirms that in the absence of milk (or another naturalsource of substrates) the addition of thiocyanate (as substrate) andascorbate (as a source of peroxide) is essential for inhibition ofStreptococcus uberis.

Note that in FIG. 6, none of the additives were totally inhibitory ontheir own. The samples labeled ‘0’ in the figure are buffer-only andadditive-only samples.

In order to determine conclusively that the total cationic fraction isat work in a synergistic way, MIC experiments were set up usingStaphylococus aureus as the pathogens. A target formulation of sodiumthiocyanate (20 ppm) and ascorbate (20 ppm) was chosen from pastexperimental work. The cationic fraction was fractionated bysize-exclusion chromatography into six (6) individual sub-fractions,each containing a major bioactive protein constituent of the totalcationic fraction.

Each of these six (6) individual fractions was then recombined to form aseventh treatment. Finally, an unfractionated cationic fraction wastested as an eighth treatment. Concentrations of each cationic fractionwere chosen such that each sub-fraction protein content from Table 2 wasadjusted so that it was equivalent to its concentration in therecombined sample.

FIG. 7 shows the growth of Streptococcus uberis after 12 hr for eachsample. Note that for this pathogen, the Lp fraction itself shows asmuch inhibition as the total cationic fraction. FIG. 8 shows the growthof Escherichia coil after 18 hr for each sample. For this pathogen, thetotal cationic fraction is required to achieve maximum inhibition. Thisis also the case for Staphylococcus aureus (FIG. 9). The conclusion fromthese experiments is that, in order to achieve a target formulationactive against all three major mastitis pathogens, the total cationicfraction is required. Recombining individual sub-fractions could beused, however, a total eluted fraction would be preferred.

At this stage, there is strong evidence that a total cationic fractionfrom the milk inhibits the growth of all three of the most commonmastitis pathogens to varying degrees. While pathogen-specificformulations could be made, we also believe that a formulation can beachieved that can be commonly used against all three pathogens.

4. Test of Growth in Full Cream Milk and Nutrient Media

The effect of the cationic fraction on the growth of Streptococcusuberis in full cream milk was tested, with results shown in FIG. 10.

At time zero autoclaved milk was inoculated with 0.1 ml of Streptococcusuberis ( 1/1000 dilution of logarithmic phase growth in trypticase soybroth). After two hours cationic fraction at a final concentration of 5mg protein/ml was added to two flasks and two were kept as controls.Samples were removed for plate counts at hourly intervals. The growthcurves (average of the plate counts) are shown in FIG. 10. The additionof the cationic fraction has inhibited the growth of Streptococcusuberis while the control has reached maximum growth in 7 hours. Thisexperiment shows that there was no requirement for the addition ofthiocyanate or ascorbate when Streptococcus uberis was grown in milk.

The effect of the cationic fraction on the growth of Escherichia coiland Staphylococus aureus is shown in FIGS. 11 and 12.

5. Efficacy Trial

The applicant is undertaking efficacy trials in the next six months.

The basis for this trial is as follows:

-   -   Aims: determine efficiency of treatment, and whether there are        any toxicity issues with either the cationic fraction or        additives/carries.    -   The carrier used in the trial is likely to be Ringer's        salts—however this may differ from the carrier used in the final        commercial formulation.    -   The full cationic fraction and additives are being used for the        trial.    -   A repeat milk growth curve experiment is to be used to determine        the desired final concentration.    -   The concentrations to be used are as follows (these may be        higher than the final formulation):        -   Cationic fraction: 50-84 mg/ml        -   NaSCN: 20-100 ppm        -   Ascorbate: 20-100 ppm        -   Monoglycerol: 5-20 ppm    -   Size of dose is to be 10 ml, and will aim for 3 doses    -   Will focus on Streptococcus uberis sub-clinical mastitis        initially, will also possibly look at Staphylococus aureus.    -   Will initially look at 15 cases of sub clinical Streptococcus        uberis mastitis to ensure at least 10 valid treatment subjects.    -   Selection criteria—no exclusions will be made on lactation        stage, age or breed.

Aspects of the present invention have been described by way of exampleonly and it should be appreciated that modifications and additions maybe made thereto without departing from the scope thereof.

REFERENCES

Bramley, A. J., Dodd, F. H. 1984. Reviews on the progress of dairyscience—Mastitis Control. J. Dairy. Res. 51: 481-512

Dillehay D. L., Webb S. J., Schmelz E.-M., Merrill A. H. Jr. Dietarysphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1mice. J. Nutr. 1994; 124:615-620

Merrill, A. H., Schmelz, E-M., Wang, E., Dillehay, D. L., Rice, L. G.,Filmore Meredith, and Riley, R. T. Importance of Sphingolipids andInhibitors of Sphingolipid Metabolism as Components of Animal Diets. TheJournal of Nutrition.127 (5) May 1997. 830S-833S

Isaacs C. E., Litov R. E., Thormar H. 1995. Antimicrobial activity oflipids added to human milk, infant formula, and bovine milk. Journal ofNutritional Biochemistry. 6: 362-366

Kussendrager, K. D. and van Hooijdonk, A. C. M. 2000. Lactoperoxidase:physico-chemical properties, occurrence, mechanism of action andapplications. British Journal of Nutrition 84: Suppl. 1, S19-S25

Malinowski, E., Klossowska, A., Kaczmarowski, M., Lassa, H., and Kuzma,K. 2002. Antimicrobial Susceptibility of Staphylococci Isolated fromAffected with Mastitis Cows. Bull. Vet. Inst. Pulawy. 46: 289-294

Merrill, A. H., Jr. & Sweeley, C. C. (1996) Sphingolipid metabolism andcell signalling. In: New Comprehensive Biochemistry: Biochemistry ofLipids, Lipoproteins, and Membranes (Vance, D. E. & Vance, J. E., eds.),pp. 309-338. Elsevier Science, Amsterdam, The Netherlands

Newburg, D. S., 1996. Oligosaccharides and glycoconjugates in humanmilk: their role in host defense. J. Mann. Gland Biol. Neoplasia 1,271-282.

Reiter, B and Oran, J. D. 1967. Bacterial inhibitors in milk and otherbiological fluids. Nature (Lond.) 216: 328-33

Schanbacher, F. L., Smith, K. L. 1975. Formation and role of unusualwhey proteins and enzymes: relation to mammary function. J. Dairy Sci.58: 1048-1062

Smolenski, G., Haines, S., Kwan, F. Y.-S., Bond, J., Farr, V., Davis, S.R., Stelwagen, K. and Wheeler, T. 2007. Characterisation of Host Defenceproteins in Milk using a Proteomic approach. J. Proteome Research 6(1):207-215

Talhouk, R. S., Neiswander, R. L., Scanbacher, F. I. 1996. Developmentalregulation and partial characterization of growth factors in the bovinemammary gland. J. Repro. Fert. 106: 221-230

1-52. (canceled)
 53. A treatment formulation for the treatment orprevention of microbial infection which includes a treatment compositionextracted from whole milk, processed milk or a milk-derived substance,wherein the composition contains a cationic fraction which includes anycomponents of the whole milk, processed milk or milk-derived substancewith an isoelectric point of or greater than substantially 6.8.
 54. Thetreatment formulation of claim 53 wherein the cationic fraction includesall components of the whole milk, processed milk or milk-derivedsubstance with an isoelectric point of or greater than substantially6.8.
 55. The treatment formulation of claim 53 wherein the formulationincludes one or more of the following:
 1. a peroxidase substrate, suchas sodium thiocyanate, and/or
 2. hydrogen peroxide or a source ofhydrogen peroxide, such as ascorbate or ascorbic acid.
 56. The treatmentformulation of claim 53 wherein the treatment composition includeschitinase-like protein (CLP-1).
 57. The treatment formulation of claim53 wherein the formulation includes a cell lysing substance.
 58. Thetreatment formulation of claim 53 wherein the treatment compositionincludes at least lactoferrin, lactoperoxidase and angiogenin.
 59. Thetreatment formulation of claims 53 wherein the treatment compositionincludes a mixture of cationic peptides.
 60. The treatment formulationof claim 53 wherein the treatment composition includes one or more ofthe following: N-acetyl glucosaminidase, serum amyloid A, β defensin,lysozyme, at least one immunoglobulin or at least one growth factor. 61.The treatment formulation of claim 53 wherein at least part of thetreatment composition is extracted “on-farm”, during or directly afterthe milking process.
 62. A medicament formed from the treatmentformulation as claimed in claim 53 which includes one or more of thefollowing: antibiotics, analgesics, carriers, buffers, preservatives,excipients, controlled release components, hardening or any otherpharmaceutically acceptable component.
 63. A method of treating orpreventing microbial infection using the treatment formulation asclaimed in claim 1, the method comprising applying the treatmentformulation into or onto the infection site.
 64. A treatment formulationfor the treatment or prevention of bovine mastitis which includes atreatment composition extracted from whole milk, processed milk or amilk-derived substance, wherein the composition contains a cationicfraction which includes any components of the whole milk, processed milkor milk-derived substance with an isoelectric point of or greater thansubstantially 6.8.
 65. The treatment formulation of claim 64 thatincludes a cell lysing substance.
 66. The treatment formulation of claim64 wherein the formulation includes one or more of the following:
 1. aperoxidase substrate, such as sodium thiocyanate, and/or
 2. hydrogenperoxide or a source of hydrogen peroxide, such as ascorbate or ascorbicacid.
 67. The treatment formulation of claim 64 wherein the treatmentcomposition includes chitinase-like protein (CLP-1).
 68. The treatmentformulation of claim 65 wherein the cell lysing substance ismonoglyceride.
 69. The treatment formulation of claim 64 wherein thetreatment composition includes at least lactoferrin, lactoperoxidase andangiogenin.
 70. The treatment formulation of claim 64 that includes amixture of cationic peptides.
 71. The treatment formulation of claim 64that includes one or more of the following: N-acetyl glucosaminidase,serum amyloid A, β defensin, lysozyme, at least one immunoglobulin or atleast one growth factor.
 72. The treatment formulation of claim 64wherein at least part of the treatment composition is extracted“on-farm”, during or directly after the milking process.
 73. Amedicament, such as a teat seal, teat spray, teat wipe, udder/teat wash,milking cluster backflush solution or intramammary formulation, formedfrom the treatment formulation as claimed in claim 64 and which mayinclude one or more of the following: antibiotics, analgesics, carriers,buffers, preservatives, excipients, controlled release components,hardening or any other pharmaceutically acceptable component.
 74. Amethod treating or preventing bovine mastitis using a treatmentformulation as claimed in claim 64, the method comprising applying thetreatment formulation, medicament or item into or onto a bovine teat.